Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist Secukinumab in Psoriasis Patients
Stefanie Hölsken,1 Frederik Krefting,2 Senta Mühlhaus,2 Daniela Bese,2 Manfred Schedlowski,1,3 Wiebke Sondermann2 1Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 2Department of Dermatology, Venereology and Allerg...
Saved in:
Main Authors: | Hölsken S, Krefting F, Mühlhaus S, Bese D, Schedlowski M, Sondermann W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2025-01-01
|
Series: | Psoriasis: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/shaping-treatment-expectation-to-optimize-efficacy-of-interleukin-17a--peer-reviewed-fulltext-article-PTT |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing Psychosocial Burden in Psoriasis Patients Using the PRISM-RII Tool: A Comprehensive Evaluation
by: Elif Afacan Yıldırım, et al.
Published: (2025-01-01) -
Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01) -
Effects of interleukin-12/23 inhibitors and interleukin-17 inhibitors on myocardial functions in patients with severe psoriasis
by: Leyla Baykal Selçuk, et al.
Published: (2024-12-01) -
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
by: Christov S, et al.
Published: (2025-01-01) -
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
by: Federico Pirro, et al.
Published: (2025-01-01)